APPLICATION
Application Note
The peptide is used for blocking the antibody activity of anti-CIKS/Act1 (cat. No 5974). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37ºC.
Product Note
This peptide blocks GTX26139.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Traf3 Interacting Protein 2 , Act1 , C6Orf2 , C6Orf4 , C6Orf5 , C6Orf6 , Candf8 , Ciks , Psors13 , Traf3Ip2
Background
CIKS (for connection to IKK and SAPK / JNK), also called Act 1 (for NFkappaB Activator 1), is a novel protein that associates with and activates IKK (IkappaB kinase). CIKS / Act1 also activates ATF (Activating Transcription Factor) and AP-1 (Activator Protein 1) through Jun Kinase (JNK). CIKS / Act 1 is ubiquitously expressed in human tissues.
Research Area
REFERENCE
There are currently no references for CIKS peptide (GTX26090). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for CIKS peptide (GTX26090). Be the first to share your experience with this product.